RxDoctor Payments Data

Frank Galante, MD

Psychiatry · Batavia, NYNPI 1144530882

Payments from drug & device makers

$6,311in general payments, 2019–2025

Across 94 payments — averaging $67.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$1K
  • AbbVie$957
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$726
  • Alkermes, Inc.$674
  • Otsuka America Pharmaceutical, Inc.$610
  • Neurocrine Biosciences, Inc.$460
  • plus $1K from 8 others

What the payments were for

  • Food & beverage$6,19998%
  • Education$1112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,311 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$16,376
Medicare patients
40
Services billed
130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate102$357,881
AustedoDeutetrabenazine17$126,725
Austedo XrDeutetrabenazine14$84,500
VraylarCariprazine Hcl37$61,668
PerserisRisperidone14$31,447
LybalviOlanzapine/Samidorphan Malate18$30,573
Hydroxyzine Hcl214$9,906
Clozapine72$6,820
Aripiprazole131$5,823
Fluphenazine Hcl27$4,527
Divalproex Sodium ErDivalproex Sodium56$3,607
Clozapine OdtClozapine14$3,397
Fluphenazine Decanoate25$3,181
Sertraline Hcl99$3,037
Olanzapine135$2,872

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$113$357,881102 claims
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$1,460$211,22531 claims
AbbVieVraylar$957$61,66837 claims
Indivior Inc.Perseris$52$31,44714 claims
Alkermes, Inc.Lybalvi$674$30,57318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Batavia

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →